在免疫球蛋白A腎病症中非標籤使用mycophenolate mofetil:系統性評論和元分析
Luda Feng1, Xuan Song1, Xinyi Shi2
1Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
American journal of nephrology
|September 25, 2024
概括
菌酸莫菲蒂尔 (MMF) 通过减少损伤和蛋白尿症,在治疗免疫球蛋白A脏病 (IgAN) 中表现有前途. 然而,MMF使用与感染风险增加有关,需要仔细考虑.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫抑制疗法 免疫抑制疗法
- 临床试验 临床试验
背景情况:
- 免疫球蛋白A脏病 (IgAN) 是一种常见的淋巴细胞疾病.
- 甲酸莫菲提尔 (MMF) 经常被用于Igan的非标签,但其有效性和安全性仍在争论中.
- 现有的文献缺乏关于MMF在IGAN患者中的益处和风险的一致证据.
研究的目的:
- 在免疫球蛋白A脏病 (IgAN) 患者中系统地评估mycophenolate mofetil (MMF) 的疗效和安全性.
- 综合来自随机对照试验 (RCT) 的证据,将MMF与Igan中的安慰剂或标准护理进行比较.
- 评估货币货币基金对关键结局和不良事件的影响.
主要方法:
- 在多个数据库 (PubMed,Embase等) 的系统文献搜索. 在2023年8月之前.
- 包括RCT比较MMF治疗与安慰剂或作为IGAN患者的附加治疗.
- 进行重复查,偏差风险评估和数据提取.
- 使用固定或随机效应模型组合数据的元分析.
- 主要结局包括复合结局 (MAKDE),血清肌素的翻倍,末期脏疾病 (ESRD) 和死亡.
主要成果:
- 对13项与918名参与者进行的RCT的分析显示,MMF减少了主要不良脏事件 (MAKDE) (RR,0.32;95% CI,0.13-0.77).
- 货币货币基金显著降低了蛋白尿 (RR,1.41;95% CI,1.22-1.64) 和血清肌二倍的可能性 (RR,0.32;95% CI,0.14-0.72).
- 在ESRD发生率或CKD进展方面没有观察到显著差异,但MMF增加了感染风险 (RR, 2.20;95% CI, 1.21-4.00).
结论:
- 在Igan患者中,MMF显示出减轻损伤和蛋白尿的潜力,其证据是减少MAKDE和肌素的翻倍.
- 在IGAN中观察到的MMF的益处伴随着感染风险的增加.
- 需要进一步的跨区域和跨种族研究来验证MMF在不同Igan群体中的长期疗效和安全性.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
119
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
119
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Drugs for Treatment of Ulcerative Colitis in IBD
129
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
129
Kidney Transplant II: Surgical Procedure
2
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
2


